News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,472 Results
Type
Article (14439)
Company Profile (103)
Press Release (258930)
Section
Business (89199)
Career Advice (475)
Deals (15526)
Drug Delivery (68)
Drug Development (38956)
Employer Resources (49)
FDA (6686)
Job Trends (6394)
News (154259)
Policy (14490)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (501)
Accelerated approval (2)
Adcomms (8)
Allergies (33)
Alliances (23546)
ALS (37)
Alzheimer's disease (408)
Antibody-drug conjugate (ADC) (39)
Approvals (6722)
Artificial intelligence (107)
Autoimmune disease (8)
Automation (3)
Bankruptcy (150)
Best Places to Work (4567)
BIOSECURE Act (9)
Biosimilars (56)
Biotechnology (42)
Bladder cancer (27)
Brain cancer (15)
Breast cancer (84)
Cancer (676)
Cardiovascular disease (74)
Career advice (417)
Career pathing (11)
CAR-T (33)
Cell therapy (104)
Cervical cancer (6)
Clinical research (32828)
Collaboration (332)
Compensation (138)
Complete response letters (17)
COVID-19 (792)
CRISPR (19)
C-suite (118)
Cystic fibrosis (36)
Data (703)
Denatured (15)
Depression (9)
Diabetes (84)
Diagnostics (1437)
Digital health (1)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (57)
Drug pricing (63)
Drug shortages (13)
Duchenne muscular dystrophy (33)
Earnings (32728)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (38616)
Executive appointments (360)
FDA (7116)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (209)
Gene editing (37)
Generative AI (8)
Gene therapy (105)
GLP-1 (350)
Government (1380)
Grass and pollen (2)
Guidances (15)
Healthcare (3854)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (37)
Indications (13)
Infectious disease (825)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (60)
IPO (5981)
IRA (29)
Job creations (2057)
Job search strategy (383)
Kidney cancer (7)
Labor market (10)
Layoffs (184)
Leadership (3)
Legal (3468)
Liver cancer (22)
Lung cancer (102)
Lymphoma (63)
Machine learning (1)
Management (16)
Manufacturing (147)
MASH (32)
Medical device (1447)
Medtech (1449)
Mergers & acquisitions (9737)
Metabolic disorders (261)
Multiple sclerosis (28)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (7)
Neuroscience (597)
NextGen: Class of 2025 (1639)
Non-profit (629)
Northern California (720)
Now hiring (7)
Obesity (149)
Opinion (123)
Ovarian cancer (23)
Pain (50)
Pancreatic cancer (17)
Parkinson's disease (46)
Partnered (7)
Patents (107)
Patient recruitment (34)
Peanut (11)
People (29030)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8674)
Phase II (13891)
Phase III (12382)
Pipeline (452)
Podcasts (46)
Policy (60)
Postmarket research (1464)
Preclinical (3476)
Press Release (26)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (125)
Rare diseases (167)
Real estate (2651)
Recruiting (17)
Regulatory (10473)
Reports (14)
Research institute (601)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (38)
Series A (37)
Series B (11)
Service/supplier (3)
Sickle cell disease (32)
Southern California (747)
Special edition (6)
Spinal muscular atrophy (80)
Sponsored (7)
Startups (1641)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (7320)
Vaccines (163)
Venture capitalists (15)
Webinars (10)
Weight loss (102)
Women's health (9)
Worklife (3)
Date
Today (40)
Last 7 days (259)
Last 30 days (1019)
Last 365 days (12677)
2025 (3250)
2024 (13159)
2023 (15007)
2022 (20350)
2021 (20908)
2020 (19742)
2019 (15470)
2018 (12093)
2017 (14334)
2016 (13499)
2015 (15969)
2014 (12749)
2013 (10848)
2012 (11630)
2011 (12134)
2010 (11111)
Location
Africa (327)
Alabama (14)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20679)
Australia (2687)
California (1748)
Canada (894)
China (232)
Colorado (80)
Connecticut (74)
Delaware (65)
Europe (40679)
Florida (318)
Georgia (49)
Idaho (10)
Illinois (196)
India (15)
Indiana (130)
Iowa (1)
Japan (87)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (24)
Maryland (261)
Massachusetts (1493)
Michigan (28)
Minnesota (93)
Missouri (24)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (763)
New Mexico (7)
New York (523)
North Carolina (387)
North Dakota (2)
Northern California (720)
Ohio (55)
Oklahoma (4)
Oregon (17)
Pennsylvania (433)
Puerto Rico (8)
Rhode Island (7)
South America (512)
South Carolina (3)
Southern California (747)
Tennessee (34)
Texas (229)
Utah (34)
Virginia (73)
Washington D.C. (29)
Washington State (122)
Wisconsin (15)
273,472 Results for "prolong pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)
February 5, 2025
·
2 min read
Press Releases
Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)
November 13, 2024
·
3 min read
Press Releases
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
March 26, 2025
·
13 min read
Press Releases
U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study
October 30, 2024
·
3 min read
Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting
Thryv Therapeutics Inc. today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA.
May 7, 2024
·
1 min read
Press Releases
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
December 11, 2024
·
19 min read
Press Releases
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
December 11, 2024
·
19 min read
Press Releases
Neurim Pharmaceuticals Receives Positive CHMP Opinion On Slenyto® (Pediatric Prolonged-Release Melatonin) For The Treatment Of Insomnia In Children With Neurogenetic Disorders (NGDs)
July 31, 2024
·
4 min read
Press Releases
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
October 10, 2024
·
19 min read
Press Releases
Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting
August 1, 2024
·
6 min read
1 of 27,348
Next
